Naohiro Yanagimura, Satoshi Watanabe, Toshiaki Kikuchi. Combined PARP and PD-L1 inhibition: a promising treatment option for relapsed small-cell lung cancer. Journal of thoracic disease. 2024. 16. 6. 4075-4078
Satoshi Watanabe, Kazuko Sakai, Naoya Matsumoto, Jun Koshio, Akira Ishida, Tetsuya Abe, Daisuke Ishikawa, Tomohiro Tanaka, Ami Aoki, Tomosue Kajiwara, et al. Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501). Cancers. 2022. 15. 1
Kohei Kushiro, Satoshi Watanabe, Yuka Goto, Toshiya Fujisaki, Naohiro Yanagimura, Aya Ohtsubo, Satoshi Shoji, Koichiro Nozaki, Tomohiro Tanaka, Yu Saida, et al. Efficacy and safety of amrubicin therapy after chemoimmunotherapy in small cell lung cancer patients. Translational lung cancer research. 2022. 11. 9. 1858-1865
Chiaki Suzuki, Akihiro Nishiyama, Sachiko Arai, Shoichiro Tange, Atsushi Tajima, Azusa Tanimoto, Koji Fukuda, Yohei Takumi, Hiroshi Kotani, Shinji Takeuchi, et al. Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1-rearranged tumor cells. Cancer science. 2022. 113. 7. 2323-2335
Naohiro Yanagimura, Shinji Takeuchi, Koji Fukuda, Sachiko Arai, Azusa Tanimoto, Akihiro Nishiyama, Naohisa Ogo, Hiroyuki Takahashi, Akira Asai, Satoshi Watanabe, et al. STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis. NPJ precision oncology. 2022. 6. 1. 11-11